Based on the Eagle Pharmaceuticals Inc stock forecast from 0 analysts, the average analyst target price for Eagle Pharmaceuticals Inc is not available over the next 12 months. Eagle Pharmaceuticals Inc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Eagle Pharmaceuticals Inc is Slightly Bullish , which is based on 9 positive signals and 5 negative signals. At the last closing, Eagle Pharmaceuticals Inc’s stock price was USD 1.30. Eagle Pharmaceuticals Inc’s stock price has changed by +12.07% over the past week, +10.17% over the past month and -77.31% over the last year.
No recent analyst target price found for Eagle Pharmaceuticals Inc
No recent average analyst rating found for Eagle Pharmaceuticals Inc
Company Overview Eagle Pharmaceuticals Inc
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-small cell lung cancer and mesothelioma; EA-114 (fulvestrant) for HR+/HER- breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an antitoxin agent for the treatment of severe pneumonia in combination with traditional antibacterial drugs; and AOP Orphan Pharmaceuticals GmbH for the commercial rights of Landiolol, a novel therapeutic product candidate for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat breast cancer (HR+/HER2-) and high-risk metastatic sarcomas. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey. Read Less
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermi...Read More
Frequently Asked Questions About Eagle Pharmaceuticals Inc (EGRX) Stock
Stock Target Advisor's fundamental analysis for Eagle Pharmaceuticals Inc's stock is Slightly Bullish .
Unfortunately we do not have enough data on EGRX's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on EGRX's stock to indicate what its average analyst target is.
EGRX stock's Price/Earning ratio is 1.76.
Our analysis grades EGRX stock's Price / Earning ratio at C. This means that EGRX stock's Price/Earning ratio is above 25% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the OTC exchange.
Based on this EGRX may be undervalued for its sector.
The last closing price of EGRX's stock was USD 1.30.
The most recent market capitalization for EGRX is USD 0.02B.
Unfortunately we do not have enough analyst data on EGRX's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Eagle Pharmaceuticals Inc's stock.
As per our most recent records Eagle Pharmaceuticals Inc has 134 Employees.
Eagle Pharmaceuticals Inc's registered address is 50 Tice Boulevard, Woodcliff Lake, NJ, United States, 07677.
You can get more information about it from Eagle Pharmaceuticals Inc's website at https://www.eagleus.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
Underpriced compared to book value
The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior capital utilization
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Highly leveraged
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Eagle Pharmaceuticals Inc (EGRX) Stock
Stock Target Advisor's fundamental analysis for Eagle Pharmaceuticals Inc's stock is Slightly Bullish .
Unfortunately we do not have enough data on EGRX's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on EGRX's stock to indicate what its average analyst target is.
EGRX stock's Price/Earning ratio is 1.76.
Our analysis grades EGRX stock's Price / Earning ratio at C. This means that EGRX stock's Price/Earning ratio is above 25% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the OTC exchange.
Based on this EGRX may be undervalued for its sector.
The last closing price of EGRX's stock was USD 1.30.
The most recent market capitalization for EGRX is USD 0.02B.
Unfortunately we do not have enough analyst data on EGRX's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Eagle Pharmaceuticals Inc's stock.
As per our most recent records Eagle Pharmaceuticals Inc has 134 Employees.
Eagle Pharmaceuticals Inc's registered address is 50 Tice Boulevard, Woodcliff Lake, NJ, United States, 07677.
You can get more information about it from Eagle Pharmaceuticals Inc's website at https://www.eagleus.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for EGRX !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
